MindMaze Therapeutics Holding (XSWX:MMTX) 12-1 Month Momentum %: N/A% (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MMTX MindMaze Therapeutics Holding SA XSWX:MMTX
4 GF Score
Price CHF0.16
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding 12-1 Month Momentum %?

MindMaze Therapeutics Holding XSWX:MMTX +3.67% 4 12-1 Month Momentum % is N/A% as of Jul. 25, 2026. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review. Among 1,361 Biotechnology companies, MindMaze Therapeutics Holding ranks worse than 73475.31% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-25), MindMaze Therapeutics Holding's 12-1 Month Momentum % is N/A%.

The industry rank for MindMaze Therapeutics Holding's 12-1 Month Momentum % or its related term are showing as below:

XSWX:MMTX's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -18.13
* Ranked among companies with meaningful 12-1 Month Momentum % only.

MindMaze Therapeutics Holding  (XSWX:MMTX) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

MindMaze Therapeutics Holding 12-1 Month Momentum % Related Terms

XSWX:MMTX
4GF Score
MindMaze Therapeutics Holding SA XSWX:MMTX
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding  (XSWX:MMTX) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a 12-1 Month Momentum % of N/A% as of Jul. 25, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on MindMaze Therapeutics Holding and its competitors. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 1361 companies in the Biotechnology industry.
Is MindMaze Therapeutics Holding's 12-1 Month Momentum % too high?
MindMaze Therapeutics Holding's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 1361 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 1361 companies for 12-1 Month Momentum %. This places MindMaze Therapeutics Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current 12-1 Month Momentum % is N/A% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTXz:UK
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score

Get the complete analysis for XSWX:MMTX

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.16
Price